Long-term efficacy, safety, and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomised controlled trial.
Dorota Maria KrasowskaT GambichlerC CortesAmir HorevN CompagnoS S DahaleP PapanastasiouD KeefePublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Secukinumab demonstrated sustained long-term efficacy (up to 2 years) and a favourable safety profile (~320 PY of treatment) in paediatric patients with severe chronic plaque psoriasis.